Table 1 Patient characteristics at baseline
Parameter | Placebo | Pemafibrate | All | ||
|---|---|---|---|---|---|
0.1 mg/day | 0.2 mg/day | 0.4 mg/day | |||
n | 298 | 127 | 584 | 244 | 1253 |
Age, years | 54.9 ± 11.3 | 51.8 ± 11.2 | 55.2 ± 11.5 | 52.8 ± 11.3 | 54.3 ± 11.4 |
Age ≥ 65 years | 62 (20.8) | 16 (12.6) | 130 (22.3) | 40 (16.4) | 248 (19.8) |
Female | 53 (17.8) | 11 (8.7) | 94 (16.1) | 26 (10.7) | 184 (14.7) |
Body weight, kg | 75.1 ± 13.4 | 76.7 ± 12.0 | 75.2 ± 13.9 a | 74.3 ± 12.5 | 75.2 ± 13.3 b |
BMI, kg/m2 | 26.91 ± 3.61 | 27.06 ± 3.61 | 27.08 ± 3.87 a | 26.25 ± 3.45 | 26.87 ± 3.71 b |
BMI ≥ 25 kg/m2 | 200 (67.1) | 87 (68.5) | 388 (66.4) | 145 (59.4) | 820 (65.4) |
Type 2 diabetes | 116 (38.9) | 23 (18.1) | 219 (37.5) | 91 (37.3) | 449 (35.8) |
Hypertension | 149 (50.0) | 43 (33.9) | 322 (55.1) | 88 (36.1) | 602 (48.0) |
Fatty liver | 143 (48.0) | 28 (22.0) | 295 (50.5) | 68 (27.9) | 534 (42.6) |
Statin use | 178 (59.7) | 45 (35.4) | 382 (65.4) | 72 (29.5) | 677 (54.0) |
TG, mmol/L | 3.74 ± 1.59 | 3.77 ± 1.21 | 3.72 ± 1.55 | 3.71 ± 1.54 | 3.73 ± 1.52 |
HDL-C, mmol/L | 1.14 ± 0.25 | 1.10 ± 0.20 | 1.14 ± 0.25 | 1.10 ± 0.39 | 1.13 ± 0.28 |
non HDL-C, mmol/L | 4.35 ± 0.82 | 4.52 ± 0.81 | 4.25 ± 0.89 | 4.54 ± 0.91 | 4.36 ± 0.88 |
LDL-Cc, mmol/L | 3.18 ± 0.88 | 3.34 ± 0.83 | 3.07 ± 0.90 | 3.37 ± 0.90 | 3.18 ± 0.89 |
TC, mmol/L | 5.49 ± 0.86 | 5.62 ± 0.86 | 5.39 ± 0.91 | 5.65 ± 0.95 | 5.49 ± 0.90 |
HbA1c, % | 6.30 ± 0.77 | 5.91 ± 0.66 | 6.31 ± 0.83 | 6.24 ± 0.76 | 6.26 ± 0.80 |
eGFRd, mL/min/1.73 m2 | 77.3 ± 17.4 | 76.7 ± 15.6 | 78.3 ± 16.4 | 78.6 ± 15.8 | 77.9 ± 16.4 |